Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Should we purge?

W I Bensinger

    Bone Marrow Transplantation
    |March 7, 1998
    PubMed
    Summary
    This summary is machine-generated.

    Relapse after autologous stem cell transplantation is common. Current evidence is limited on whether purging stem cell grafts improves outcomes, with potential risks to immune reconstitution.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

    Bone marrow transplantation·2016
    Same author

    A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.

    Blood cancer journal·2016
    Same author

    A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

    Bone marrow transplantation·2015
    Same author

    Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2015
    Same author

    Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.

    Bone marrow transplantation·2015
    Same author

    Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.

    Gene therapy·2014
    Same journal

    Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

    Bone marrow transplantation·2026
    Same journal

    A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

    Bone marrow transplantation·2026
    Same journal

    Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

    Bone marrow transplantation·2026
    Same journal

    Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

    Bone marrow transplantation·2026
    Same journal

    Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

    Bone marrow transplantation·2026
    Same journal

    A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood.

    Bone marrow transplantation·2026
    See all related articles

    Area of Science:

    • Hematology
    • Transplantation immunology
    • Oncology

    Background:

    • Relapse post-autologous stem cell transplant (ASCT) is a major cause of treatment failure, attributed to residual host disease or reinfused tumor cells.
    • Graft purging to eliminate tumor cells is theoretically appealing, with extensive literature, yet clinical data supporting its efficacy are scarce.

    Discussion:

    • Purging techniques may inadvertently harm beneficial immune cells (T cells) or essential stem cells, potentially leading to delayed hematopoietic or T cell recovery.
    • The lack of robust evidence necessitates a re-evaluation of current graft purging strategies in ASCT.

    Key Insights:

    • Limited data exist to confirm that purging autologous stem cell grafts improves relapse rates or disease-free survival.
    • Some purging methods may negatively impact patient recovery, including delayed immune reconstitution.

    Related Experiment Videos

    Outlook:

    • There is a critical need for large, well-designed clinical trials to definitively assess the impact of specific graft purging techniques on ASCT outcomes.
    • Future research should focus on validating purging efficacy and safety to optimize ASCT protocols and improve patient survival.